Company Filing History:
Years Active: 2023
Title: Kuo-Pao Lai: Innovator in Immunogenic Glycan Compositions
Introduction
Kuo-Pao Lai is a distinguished inventor based in Taipei, Taiwan. He has made significant contributions to the field of immunogenic and therapeutic glycan compositions. His work focuses on developing innovative solutions for treating proliferative diseases, particularly cancer.
Latest Patents
Kuo-Pao Lai holds a patent for "Immunogenic/therapeutic glycan compositions and uses thereof." This patent encompasses compositions that include Globo series antigens, such as SSEA-4, Globo H, or SSEA-3 glycoconjugates, along with therapeutic adjuvants like OBI-821 or OBI-834. The therapeutic conjugates are designed to act as cancer vaccines, enhancing the body's immune response against abnormal cells. The compositions aim to reduce disease severity, prevent disease onset, and improve overall patient outcomes.
Career Highlights
Kuo-Pao Lai is currently associated with Obi Pharma Inc., where he continues to advance his research and development efforts. His innovative work has positioned him as a key figure in the biotechnology sector, particularly in the development of cancer therapies.
Collaborations
Kuo-Pao Lai collaborates with notable colleagues, including Cheng-Der Tony Yu and Peiwen Yu. Their combined expertise contributes to the advancement of therapeutic solutions in the field of immunology.
Conclusion
Kuo-Pao Lai's contributions to immunogenic glycan compositions represent a significant advancement in cancer treatment. His innovative approaches and collaborations continue to pave the way for new therapeutic options.